vimarsana.com
Home
Live Updates
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint : vimarsana.com
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint : vimarsana.com
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpointData included observations of immune activation with...
Related Keywords
Norway ,
Oslo ,
Norwegian ,
,
Oslo University Hospital ,
Euronext Oslo Stock Exchange ,
Tetanus Epitope Targeting ,
Carlos De Sousa ,
Chief Executive Officer ,
Oslo University ,
Ultimovac Tetanus Epitope Targeting ,
Abuse Regulation ,
Norwegian Securities Trading ,
Markets ,